Publications

• Serum inflammatory profile for the discrimination of clinical subtypes in Parkinson’s disease
  Yilmaz R, Strafella A, Bernard A, Schulte C, van den Huevel L, Schneiderhan-Marra N, Knorpp T, Joos T, Leypoldt F, Geritz J, Hansen C, Apel A, Gasser T, Lang A, Berg D, Maetzler W, Marras C
  Front Neurol., 2018 Dec 21 DOI:/10.3389/fneur.2018.01123
• Low-picomolar, label-free procalcitonin analytical detection with an electrolyte-gated organic field-effect transistor based electronic immunosensor. Biosens Bioelectron
  Seshadri P, Manoli K, Schneiderhan-Marra N, Anthes U, Wierzchowiec P, Bonrad K, Di Franco C, Torsi L.
  Biosens Bioelectron. 2018 May 1;104:113-119. doi: 10.1016/j.bios.2017.12.041. Epub 2017 Dec 26.
• Validation of HAV biomarker 2A for differential diagnostic of hepatitis A infected and vaccinated individuals using multiplex serology
  Bohm K, Filomena A, Schneiderhan-Marra N, Krause G, Sievers C
  Vaccine. 2017 Oct 13;35(43):5883-5889. doi: 10.1016/j.vaccine.2017.08.089. Epub 2017 Sep 14.
• Performance of a Multiplex Serological Helicobacter pylori Assay on a Novel Microfluidic Assay Platform
  Filomena A, Guenther A, Planatscher H, Topin F, She J, Formichella L, Terradot L, Gerhard M, Joos TO, Meyer H, Schneiderhan-Marra N
  Proteomes. 2017 Oct 3;5(4). pii: E24. doi: 10.3390/proteomes5040024.
• Study of the Humoral Immune Response towards HCV Genotype 4 Using a Bead-Based Multiplex Serological Assay
  Filomena A, Göpfert JC, Duffy D, Pol S, Abdel-Hamid M, Esmat G, Fontanet A, Albert M, Joos T, Schneiderhan-Marra N
  High-Throughput. 2017; 6(4): 15.
• Development of a Bead-Based Multiplex Assay for the Analysis of the Serological Response against the Six Pathogens HAV, HBV, HCV, CMV, T. gondii, and H. pylori
  Filomena A, Pessler F, Akmatov M, Krause G, Duffy D, Gärtner B, Gerhard M, Albert M, Joos T, Schneiderhan-Marra N,
  High-Throughput. 2017; 6(4): 14.
• Inflammatory profile discriminates clinical subtypes in LRRK2-associated Parkinson's disease
  Brockmann K, Schulte C, Schneiderhan-Marra N, Apel A, Pont-Sunyer C, Vilas D, Ruiz-Martinez J, Langkamp M, Corvol JC, Cormier F, Knorpp T, Joos TO, Bernard A, Gasser T, Marras C, Schule B, Aasly JO, Foroud T, Marti-Masso JF, Brice A, Tolosa E, Berg D, Maetzler W
  Eur J Neurol. 2017 Feb;24(2):427-e6. doi: 10.1111/ene.13223.
• A standardized production pipeline for high profile targets from Mycobacterium tuberculosis
  Milewski MC, Broger T, Kirkpatrick J, Filomena A, Komadina D, Schneiderhan-Marra N, Wilmanns M, Parret AH
  Proteomics Clin Appl. 2016 Oct;10(9-10):1049-1057. doi: 10.1002/prca.201600033. Epub 2016 Aug 3.
• Personalized peptide vaccine induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient
  Loffler MW, Anoop Chandran P, Laske K, Schroeder C, Bonzheimm I, Walzer M, Hilke FJ, Trautwein N, Kowalewski DJ, Schuster H, Gunder M, Carcamo Yanez VA, Mohr C, Sturm M, Nguyen HP, Riess O, Bauer P, Nahnsen S, Nadalin S, Zieker D, Glatzle J, Thiel K, Schneiderhan-Marra N, Clasen S, Bosmuller H, Fend F, Kohlbacher O, Gouttefangeas C, Stevanovic S, Konigsrainer A, Rammensee HG
  J Hepatol. 2016 Oct;65(4):849-855. doi: 10.1016/j.jhep.2016.06.027. Epub 2016 Jul 7.
• Inflammatory profile in LRRK2-associated prodromal and clinical PD
  Brockmann K, Apel A, Schulte C, Schneiderhan-Marra N, Pont-Sunyer C, Vilas D, Ruiz-Martinez J, Langkamp M, Corvol JC, Cormier F, Knorpp T, Joos TO, Gasser T, Schule B, Aasly JO, Foroud T, Marti-Masso JF, Brice A, Tolosa E, Marras C, Berg D, Maetzler W
  J Neuroinflammation. 2016 May 24;13(1):122. doi: 10.1186/s12974-016-0588-5.
• Pre-Analytical Parameters Affecting Vascular Endothelial Growth Factor Measurement in Plasma: Identifying Confounders
  Walz JM, Boehringer D, Deissler HL, Faerber L, Goepfert JC, Heiduschka P, Kleeberger SM, Klettner A, Krohne TU, Schneiderhan-Marra N, Ziemssen F, Stahl A
  PLoS One. 2016 Jan 5;11(1):e0145375. doi: 10.1371/journal.pone.0145375. eCollection 2016.
• Bead-Based Peptide Arrays for Profiling the Specificity of Modification State-Specific Antibodies
  Filomena A, Beiter Y, Templin MF, Joos TO, Schneiderhan-Marra N, Poetz O
  Methods Mol Biol. 2015;1348:251-65. doi: 10.1007/978-1-4939-2999-3_22.
• Characterization of immunologically active drugs in a novel organotypic co-culture model of the human gut and whole blood
  Schmohl M, Schneiderhan-Marra N, Baur N, Hefner K, Blum M, Stein GM, Joos TO, Schmolz M
  Int Immunopharmacol. 2012 Oct 24;14(4):722-728. doi: 10.1016/j.intimp.2012.10.010.
• Receptor tyrosine kinase inhibitor profiling using bead-based multiplex sandwich immunoassays
  Poetz O, Schneiderhan-Marra N, Henzler T, Herget T, Joos TO
  Methods Mol Biol. 2012;795:191-202. doi: 10.1007/978-1-61779-337-0_13.
• A generic operational strategy to qualify translational safety biomarkers
  Matheis K, Laurie D, Andriamandroso C, Arber N, Badimon L, Benain X, Bendjama K, Clavier I, Colman P, Firat H, Goepfert J, Hall S, Joos T, Kraus S, Kretschmer A, Merz M, Planatscher H, Schneiderhan-Marra N
  Drug Discov Today. 2011 July; 16(13-14): 600-608. DOI 10.1016/j.drudis.2011.04.011
• Molecular indicators of non-sentinel node status in breast cancer determined in preoperative biopsies by multiplexed sandwich immunoassays
  Sauer G, Schneiderhan-Marra N, Muche R, Koretz K, Kazmaier C, Kreienberg R, Joos T, Deissler H
  J Cancer Res Clin Oncol. 2011 Aug;137(8):1175-84. Epub 2011 Apr 24.
• Triple-negative breast cancer: present challenges and new perspectives
  Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J, Monleon D, Postma GJ, Schneiderhan-Marra N, Santoro F, Wouters H, Russnes HG, Sorlie T et al.
  Mol Oncol. 2010 Jun;4(3):209-29. Epub 2010 Apr 24. doi: 10.1016/j.molonc.2010.04.006
• Multiplexed immunoassays for the analysis of breast cancer biopsies
  Schneiderhan-Marra N, Sauer G, Kazmaier C, Hsu HY, Koretz K, Deissler H, Joos TO
  Anal Bioanal Chem. 2010 Aug;397(8):3329-38. doi: 10.1007/s00216-010-3873-7. Epub 2010 Jul 18.
• Protein microarrays for personalized medicine
  Yu X, Schneiderhan-Marra N, Joos TO
  Clin Chem. 2010 Mar;56(3):376-87. Epub 2010 Jan 14. doi: 10.1373/clinchem.2009.137158
• Protein-protein-interactions in a multiplexed, miniaturized format a functional analysis of Rho GTPase activation and inhibition
  Schmohl M, Rimmele S, Potz O, Kloog Y, Gierschik P, Joos TO, Schneiderhan-Marra N
  Proteomics. 2010 Apr;10(8):1716-20. doi: 10.1002/pmic.200900597.
• Bead-based protein-protein interaction assays for the analysis of Rho GTPase signaling
  Rimmele S, Gierschik P, Joos TO, Schneiderhan-Marra N
  J Mol Recognit. 2010 Nov-Dec;23(6):543-50. doi: 10.1002/jmr.1051.
• Prediction of Nodal Involvement in Breast Cancer Based on Multiparametric Protein Analyses from Preoperative Core Needle Biopsies of the Primary Lesion.
  Sauer G, Schneiderhan-Marra N, Kazmaier C, Hutzel K, Koretz K, Muche R, Kreienberg R, Joos T, Deissler H
  Clin Cancer Res. 2008 Jun 1;14(11):3345-3353. doi: 10.1158/1078-0432.CCR-07-4802.
• A Cryptic Vascular Endothelial Growth Factor T-Cell Epitope: Identification and Characterization by Mass Spectrometry and T-Cell Assays
  Weinzierl AO, Maurer D, Altenberend F, Schneiderhan-Marra N, Klingel K, Schoor O, Wernet D, Joos T, Rammensee HG, Stevanovic S (2008)
  Cancer Res. 2008 Apr 1;68(7):2447-54. doi: 10.1158/0008-5472.CAN-07-2540
• Protein Microarrays - A Promising Tool for Cancer Diagnosis
  Schneiderhan-Marra N, Kirn A, Döttinger A, Templin M, Sauer G, Deissler H, Joos TO
  Cancer Genomics & Proteomics. 2005 Jan; 2(1): 37-42.
• Retinoblastoma susceptibility gene product pRB activates hypoxia-inducible factor-1 (HIF-1)
  Budde A, Schneiderhan-Marra N, Petersen G, Brune B
  Oncogene. 2005; 24(10): 1802-8. DOI: 10.1038/sj.onc.1208369